Resistencia antimicrobiana a Escherichia coli y Pseudomonas aeruginosa de un Hospital de nivel III-E, enero – abril 2018
No Thumbnail Available
Date
2021
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El presente trabajo tuvo como objetivo evaluar el perfil de resistencia antimicrobiana a Escherichia coli y Pseudomonas aeruginosa de un hospital de nivel III-E, enero-abril 2018. Para dicho estudio se recolectaron los informes de microbiología de las historias clínicas de pacientes hospitalizados en el servicio de Medicina Interna (11C) del Hospital Nacional Edgardo Rebagliati Martins durante el periodo enero-abril 2018. En lo referente a susceptibilidad bacteriana se encontró que Pseudomonas aeruginosa presentó una sensibilidad de 13,60% para amikacina, 10,40% para tobramicina, imipenem/cilastatina y colistina, seguido de 9,60% para gentamicina. Asimismo, Escherichia coli se reportó una sensibilidad de 10,12% para imipenem, 9,52% para ertapenem, 8,93% para meropenem, 8,33% para nitrofurantoína, seguido de 7,74% para amikacina. El perfil de resistencia antimicrobiana encontrada para Pseudomonas aeruginosa mostró tasas de 18.18% para norfloxacino, 14,55% para levofloxacino, 12,73% para gentamicina, seguido de 10,91% para meropenem e imipenem/cilastina. Frente a Escherichia coli se constató una elevada resistencia de 12,71% para levofloxacino, 11,86% para ciprofloxacino, 11,02% para norfloxacino, seguido de 8,47% para tobramicina y ácido nalidíxico.
ABSTRACT The objective of the present work was to evaluate the profile of antimicrobial resistance to Escherichia coli and Pseudomonas aeruginosa in a level III-E hospital, January-April 2018. for this study the microbiology reports of the medical records of hospitalized patients in the Internal Medicine service were collected (11C) of the Edgardo Rebagliati Martins National Hospital during the period JanuaryApril 2018. Regarding bacterial susceptibility, it was found that Pseudomonas aeruginosa presented a sensitivity of 13.60% for amikacin, 10.40% for tobramycin, imipenem / cilastatin and colistin, followed by 9.60% for gentamicin. Likewise, Escherichia coli reported a sensitivity of 10.12% for imipenem / cilastine, 9.52% for ertapenem, 8.93% for meropenem, 8.33% for nitrofurantoin, followed by 7.74% for amikacin. The antimicrobial resistance profile found for Pseudomonas aeruginosa showed rates of 18.18% for norfloxacin, 14.55% for levofloxacin, 12.73% for gentamicin, followed by 10.91% for meropenem and imipenem / cilastine. Against Escherichia coli, a high resistance of 12.71% was found for levofloxacin, 11.86% for ciprofloxacin, 11.02% for norfloxacin, followed by 8.47% for tobramycin and nalidixic acid.
ABSTRACT The objective of the present work was to evaluate the profile of antimicrobial resistance to Escherichia coli and Pseudomonas aeruginosa in a level III-E hospital, January-April 2018. for this study the microbiology reports of the medical records of hospitalized patients in the Internal Medicine service were collected (11C) of the Edgardo Rebagliati Martins National Hospital during the period JanuaryApril 2018. Regarding bacterial susceptibility, it was found that Pseudomonas aeruginosa presented a sensitivity of 13.60% for amikacin, 10.40% for tobramycin, imipenem / cilastatin and colistin, followed by 9.60% for gentamicin. Likewise, Escherichia coli reported a sensitivity of 10.12% for imipenem / cilastine, 9.52% for ertapenem, 8.93% for meropenem, 8.33% for nitrofurantoin, followed by 7.74% for amikacin. The antimicrobial resistance profile found for Pseudomonas aeruginosa showed rates of 18.18% for norfloxacin, 14.55% for levofloxacin, 12.73% for gentamicin, followed by 10.91% for meropenem and imipenem / cilastine. Against Escherichia coli, a high resistance of 12.71% was found for levofloxacin, 11.86% for ciprofloxacin, 11.02% for norfloxacin, followed by 8.47% for tobramycin and nalidixic acid.
Description
Keywords
Resistencia bacteriana, Escherichia coli, Pseudomonas aeruginosa